Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
Visa to Move European Headquarters to London’s Canary Wharf 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
CHA Biotech Co., Ltd., a biotech firm developing and manufacturing cell therapy-related optical, digital, and medical products, has partnered with CanCure, a US-based immunotherapy biotech firm. They agreed to co-develop natural killer (NK) cell therapy.
CHA Biotech confirmed its collaboration with CanCure on Monday, Jan. 29. According to The Korea Times, the company signed a material transfer agreement to design and produce an anti-MIC antibody treatment.
The NK Cells Therapy
It was explained that the anti-MIC antibody earmarks the MIC antigen (MHC class I polypeptide-related sequence) demonstrated by cancer cells. Moreover, the MIC alludes to a type of protein that plays a crucial part in regulating and controlling the NK cell killing of cancer cells. Once the NK cells identify MICA or MICB emerging from cancerous cells, the faculty to quash cancer cells diminishes.
For its project with CanCure, CHA Biotech plans to review the therapeutic effect and level of effectiveness of the combined MIC-targeted antibodies and allogeneic NK cells. CHA Biotech stated, “CanCure’s anti-MIC antibody can reverse the immune suppression of tumor-shed MIC and enhance the tumor-killing ability of NK cells, allowing NK cells more powerful control of cancer cells.”
CHA Biotech and CanCure’s Agreement
Korea Biomedical Review reported that under the agreement signed by CHA Biotech and CanCure, the South Korean biotech firm will receive a material transfer of antibodies that focuses on MHC class I antigens from the latter. After the clinical plan is finalized, the former will check the therapeutic effects of the antibodies and NK cells in different cancer models.
Lee Jung Hyun, the chief executive officer of CHA Biotech, added, “To expand and strengthen CHA Biotech’s NK cell therapy pipelines, we are pursuing multiple combination strategies with immune checkpoint inhibitors and antibodies. We are planning on increasing the speed and success rate of clinical trials for our NK cell therapy through an open innovation approach with novel biopharmaceuticals and technologies.”
Photo by: CHA Biotech Website
